SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid speculation of a potential partnership with Tesla, fueled by suggestive social media activity, with the community actively discussing the implications of such a deal and its potential to ignite a short squeeze. Bullish sentiment is building as investors anticipate upcoming catalysts, including flight demonstrations and potential military contracts, while some debate the company's ability to compete with industry peers and achieve full VTOL capabilities. The stock's high short interest adds another layer of intrigue as traders weigh the potential for significant upside.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending as part of a broader surge in quantum computing stocks, driven by interest in their potential to revolutionize industries and reduce energy consumption, especially for AI. Community discussions revolve around the high valuations of quantum companies relative to current revenue, with some cautioning against a potential bubble and others highlighting long-term growth potential. Some investors highlight the company's contracts and potential acquisitions as catalysts.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a surge in interest in quantum computing stocks, with community members debating the sustainability of its high valuation relative to revenue. Some traders are pointing to potential short squeezes, while others highlight concerns about possible dilution and unsustainable growth. The stock's significant price movement and high volatility are contributing to the heightened discussion.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending due to renewed interest in quantum computing stocks, with community members discussing the company's potential and comparing it to sector peers like RGTI and IONQ. Some traders are pointing to a recent private placement and potential government support as catalysts, while others express concerns about valuation and dilution. Overall, the conversation highlights the speculative nature of the sector and the debate between long-term potential and short-term risks.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as investors discuss a potential recovery after a significant drop, with community members pointing to strong underlying data and possible institutional manipulation as reasons for optimism. Discussions revolve around a large options purchase, fueling speculation about a potential buyout or upcoming positive news. Despite mixed sentiment, many believe the stock is oversold and poised for a rebound, citing a potentially promising drug pipeline.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending as it unveils AI partnerships with Nvidia, OpenAI, and Snowflake, exciting the community about its potential as a leader in enterprise AI automation. Discussions revolve around its shift from traditional RPA to 'Agentic AI,' with some seeing it as undervalued compared to peers like PLTR and SNOW. Despite positive news, some traders note struggles in holding gains, while others remain optimistic about long-term growth and potential rerating.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as investors discuss its high valuation relative to revenue and cash burn, with some highlighting potential short squeeze opportunities and its collaboration with NVIDIA. Community members are debating whether the current stock price reflects future potential or if it's a speculative bubble, while others point to insider selling and dilution concerns. News of Amazon disclosing a stake in IONQ has also fueled conversation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending due to speculation around potential U.S. government investment in its Greenland rare earths mine, fueled by a Reuters report. The community is discussing the possibility of a deal similar to Lithium Americas (LAC) and its potential impact, with some expecting a significant price increase. Discussions also involve the company's relationship with European Lithium ($EULIF) and potential benefits from a share buyback.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amid community discussions about potential exchange listings and upcoming partnerships, with some comparing it to early XRP. Bullish sentiment is fueled by the anticipation of the super app launch and long-term growth potential, while others are focused on technical analysis and key price levels. Community members are actively discussing staking rewards and the impact of regulatory compliance on future growth.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc ($TDOC) is trending as community members discuss a potential short squeeze and recent analyst activity, including bullish sentiment from Citron Research. Some investors believe the stock is undervalued, noting its cash flow and potential for growth in the telehealth sector, while others point to technical indicators suggesting a possible breakout. Community members are also speculating on potential catalysts such as a possible government shutdown or new contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?

Immunome (IMNM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates

Immunome (IMNM) delivered earnings and revenue surprises of +3.85% and +62.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Matches Q2 Earnings Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and +1.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences drew heightened retail investor chatter on Wednesday after the FDA awarded Rare Pediatric Disease designation to its gene editing therapy PBGENE-DMD, which targets duchenne muscular dystrophy (DMD) treatment.The stock surged as much as 9% during regular trading but reversed course to close down 7.2% at $4.24, and extended losses in after-hours trading, slipping 3.5%.The designation, which is intended to provide incentives for the development of drugs and biologics for serious and life-threatening conditions that predominantly affect individuals under age 18, could provide Precision with a priority review voucher (PRV) upon approval of the drug.PRVs can be redeemed for accelerated FDA review of a different drug or sold to other companies, creating potential for non-dilutive capital.Precision’s chief development and business officer, Cindy Atwell, said the designation supports the potential of PBGENE-DMD to deliver a “meaningful improvement and durable functional benefit” for up to 60% of patients.PBGENE-DMD is a first-in-class in vivo gene editing therapy that uses the company’s proprietary Arcus platform, designed to excise exons 45–55 of the dystrophin gene using two Arcus nucleases delivered in a single Adeno-associated virus (AAV).&nbsp;The one-time treatment aims to restore a near full-length, naturally produced dystrophin protein, considered functional in humans.In preclinical studies, PBGENE-DMD showed:<ul class="todo-list"><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Significant, durable functional improvements in a humanized DMD mouse model</label></li><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Restoration of dystrophin production in key muscle types, including cardiac and skeletal muscle</label></li><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Editing of satellite muscle stem cells, believed to be important for long-term durability</label></li></ul>&nbsp;The company is currently completing final IND-enabling toxicology studies and said it expects to begin clinical testing in 2026.Precision also said that its Arcus platform enables precise, defined therapeutic gene edits using a small, structurally distinct nuclease, supporting gene insertion, elimination, and excision.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,025% surge in 24-hour message volume.One user pointed to Precision’s cash reserves of over $80 million and described the current setup as a “good risk-reward,” suggesting the downside appears limited while the potential upside could be unlimited.<stembedurl>https://stocktwits.com/pinkal/message/619015289</stembedurl>Another user, reflecting on a much higher cost basis from early 2021, assessed whether the current dip might offer a fresh buying opportunity.<stembedurl>https://stocktwits.com/foxhedgehog/message/618993420</stembedurl>The stock has declined 9.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

The FDA designation could make Precision eligible for a valuable Priority Review Voucher, while preclinical data showed strong dystrophin restoration across key muscle groups.

Equity

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, including gene elimination...

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Precision Biosciences Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

DTIL
Precision Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DTIL News

DTIL Precision Biosciences Inc